NCT00823342View on ClinicalTrials.gov

ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy

PHASE3TerminatedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 14, 2008

Primary Completion Date

December 14, 2008

Study Completion Date

December 14, 2008

Conditions
HBe Negative Chronic Hepatitis BHepatitis B Viral Infection
Interventions
DRUG

CLEVUDINE + TENOFOVIR PLACEBO

30 MG

DRUG

CLEVUDINE IN ASSOCIATION TENOFOVIR

TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd

DRUG

TENOFOVIR + CLEVUDINE PLACEBO

TENOFOVIR 300 mg qd + CLEVUDINE Placebo

Trial Locations (1)

13285

Hôpital Saint Joseph, Marseille

Sponsors

Collaborators (2)

Gilead Sciences
Pharmasset
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

collaborator

Pharmasset

INDUSTRY

lead

French National Agency for Research on AIDS and Viral Hepatitis

OTHER_GOV